To the best of our knowledge, regarding ADCs plus PD-1/PD-L1 inhibitors in HER2-positive breast cancer, only one result from a phase II study (KATE2) has been reported and there is a lack of phase III data at present (33). Here, ERBB2 is linked to breast carcinoma.